Hospital Pharmacy - June 2020 - 180

180
6. Ross JS, Torres-Mora J, Wagle N, Jennings TA, Jones DM.
Biomarker-based prediction of response to therapy for
colorectal cancer: current perspective. Am J Clin Pathol.
2010;134:478-490.
7. Worthley DL, Leggett BA. Colorectal cancer: molecular features and clinical opportunities. Clin Biochem Rev.
2010;31(2):31-38.
8. Ahmed M, Hussain AR, Siraj AK, et al. Co-targeting of
cyclooxygenase-2 and FoxM1 is a viable strategy in inducing anticancer effects in colorectal cancer cells. Mol Cancer.
2015;14:131. doi:10.1186/s12943-015-0406-1.
9. Zhu YM, Azahri NSM, Yu DCW, Woll PJ. Effects of COX-2
inhibition on expression of vascular endothelial growth factor and interleukin-8 in lung cancer cells. BMC Cancer.
2008;10:218.
10. Temraz S, Mukherji D, Shamseddine A. Potential targets for
colorectal cancer prevention. Int J Mol Sci. 2013;14:1727917303.
11. Howe LR. Inflammation and breast cancer. Cyclooxygenase/
prostaglandin signaling and breast cancer. Breast Cancer Res.
2007;9:210.
12. Thun MJ, Jacobs EJ, Patrono C. The role of aspirin in cancer prevention. Nat Rev Clin Oncol. 2012;9(5):259-267.
doi:10.1038/nrclinonc.2011.199.
13. Liao X, Lochhead P, Nishihara R, Morikawa T, Qian ZR.
Aspirin use, tumor PIK3CA mutation, and colorectal-cancer
survival. N Engl J Med. 2012;367(17):596-1606.
14. Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal
cancer in relation to the expression of COX-2. N Engl J Med.
2007;356(21):2131-2142.
15. Coyle C, Cafferty FH, Langley RE, Langley RE, Coyle C,
Cafferty FH. Aspirin and colorectal cancer prevention and
treatment: is it for everyone? Curr Colorectal Cancer Rep.
2016;12:27-34.
16. Fajardo AM, Piazza GA. Chemoprevention in gastrointestinal
physiology and disease. Anti-inflammatory approaches for
colorectal cancer chemoprevention. Am J Physiol Gastrointest
Liver Physiol. 2015;309:G59-G70.
17. Pommergaard H, Burcharth J, Rosenberg J, Raskov H.

Aspirin, calcitriol, and calcium do not prevent adenoma recurrence in a randomized controlled trial. Gastroenterology.
2016;150(1):114-122.e4. doi:10.1053/j.gastro.2015.09.010.
18. Kato I, Lane D, Womack CR, et al. Interaction between nonsteroidal anti-inflammatory drugs and low-fat dietary intervention on colorectal cancer incidence; the Women's Health
Initiative (WHI) Dietary Modification Trial. J Am Coll Nutr.
2017;36(6):462-469. doi:10.1080/07315724.2017.1321505.
19. Coghill AE, Phipps AI, Bavry AA, et al. The association

between NSAID use and colorectal cancer mortality: results
from the Women's Health Initiative. Cancer Epidemiol
Biomarkers Prev. 2012;21(11):1966-1974.
20. Grau MV, Sandler RS, McKeown-Eyssen G, et al. Nonsteroidal
anti-inflammatory drug use after 3 years of aspirin use and
colorectal adenoma risk: observational follow-up of a randomized study. J Natl Cancer Inst. 2009;10(4):267-276.
21. Thompson P, Roe DJ, Fales L, et al. Design and baseline
characteristics of participants in a phase III randomized trial
of celecoxib and selenium for colorectal adenoma prevention.
Cancer Prev Res (Phila). 2012;5(12):1381-1394.

Hospital Pharmacy 55(3)
22. Wang Y, Zhang F, Wang J. The efficacy and safety of nonsteroidal anti-inflammatory drugs in preventing the recurrence
of colorectal adenoma: a meta-analysis and systematic review
of randomized trials. Colorectal Dis. 2014;17:188-196.
23. Hultberg DK, Angenete E, Lydrup M-L, Ruteg J, Matthiessen
P, Ruteg M. Nonsteroidal anti-inflammatory drugs and the risk
of anastomotic leakage after anterior resection for rectal. Eur J
Surg Oncol. 2017;43:1908-1914.
24. Benamouzig R, Uzzan B, Deyra J, et al. Prevention by daily
soluble aspirin of colorectal adenoma recurrence: 4-year results
of the APACC randomised trial. Gut. 2012;61:255-261.
25. Vaughan LE, Prizment A, Blair CK, Thomas W, Anderson
KE, Anderson KE. Aspirin use and the incidence of breast,
colon, ovarian, and pancreatic cancers in elderly women in
the Iowa Women's Health Study. Cancer Causes Control.
2016;27(11):1395-1402.
26. Cao Y, Nishihara R, Wu K, et al. Population-wide impact of
long-term use of aspirin and the risk for cancer. JAMA Oncol.
2016;2(6):762-769.
27. Ranger GS. The role of aspirin in colorectal cancer che
moprevention. Crit Rev Oncol Hematol. 2016;104:87-90.
doi:10.1016/j.critrevonc.2016.05.011.
28. Burn J, Gerdes A, Macrae F, et al. Long-term effect of aspirin
on cancer risk in carriers of hereditary colorectal cancer: an
analysis from the CAPP2 randomised controlled trial. Lancet.
2011;378(9809):2081-2087. doi:10.1016/S0140-6736(11)610
49-0.
29. Ishikawa H, Mutoh M, Suzuki S, et al. The preventive effects
of low-dose enteric-coated aspirin tablets on the development
of colorectal tumours in Asian patients: a randomised trial.
Gut. 2014;63:1755-1759.
30. Benamouzig R, Uzzan B, Martin A, et al. Cyclooxygenase-2
expression and recurrence of colorectal adenomas: effect of
aspirin chemoprevention. Gut. 2010;59:622-629.
31. Barry EL, Sansbury LB, Grau MV, et al. Cyclooxygenase-2
polymorphisms, aspirin treatment, and risk for colorectal
adenoma recurrence-data from a randomized clinical trial.
Cancer Epidemiol Biomarkers Prev. 2009;18(10):2726-2734.
32. Giampieri R, Restivo A, Pusceddu V, et al. The role of aspirin as antitumoral agent for heavily pretreated patients with
metastatic colorectal cancer receiving capecitabine monotherapy. Clin Colorectal Cancer. 2017;16(1):38-43.doi:10.1016/j.
clcc.2016.07.011.
33. Rothwell PM, Wilson M, Elwin C, et al. Long-term effect of
aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet. 2010;376(9754):17411750. doi:10.1016/S0140-6736(10)61543-7.
34. Lang Kuhs KA, Hildesheim A, Trabert B, et al. Association
between regular aspirin use and circulating markers of inflammation: a study within the Prostate, Lung, Colorectal and
Ovarian Cancer Screening Trial. Cancer Epidemiol Biomarkers
Prev. 2015;24(5):825-832.
35. Bertagnolli MM, Eagle CJ, Zauber AG, et al. Celecoxib for
the prevention of sporadic colorectal adenomas. N Engl J Med.
2006;355(9):873-884.
36. Chan AT, Hsu M, Zauber AG, Hawk ET, Bertagnolli MM. The
influence of UGT1A6 variants and aspirin use in a randomized
trial of celecoxib for prevention of colorectal adenoma. Cancer
Prev Res (Phila). 2012;5(1):61-73.

Hospital Pharmacy - June 2020

Table of Contents for the Digital Edition of Hospital Pharmacy - June 2020